Novel Inhibitor to Overcome Drug Resistance Induced by RAF, MEK Inhibitors
A new class of investigational medicines may help to treat patients with cancers driven by mutations in genes such as BRAF or KRAS/NRAS, including those patients who have become resistant to therapies that target BRAF directly, according to preclinical data presented at the AACR Annual Meeting 2013, held in Washington, [...]
Read more ›

